This article compares Wegovy (semaglutide) and Mounjaro (tirzepatide), two weekly injectable peptide drugs used for weight management and type 2 diabetes. It outlines their FDA-approved uses, noting that Wegovy is approved for weight loss while Mounjaro's weight-loss use is off-label. It reviews side effects, costs, and trial evidence suggesting tirzepatide produces greater weight loss than semaglutide.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.